Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2006 by Angiogenix.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Angiogenix
ClinicalTrials.gov Identifier:
NCT00343954
First received: June 21, 2006
Last updated: NA
Last verified: June 2006
History: No changes posted

June 21, 2006
June 21, 2006
Not Provided
Not Provided
  • PK and PD responses to L-citrulline
  • Endpoints will be determined as change from baseline
Same as current
No Changes Posted
Assessment of safety and tolerability of L-citrulline,
Same as current
Not Provided
Not Provided
 
PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease
Phase 1 Pharmacokinetic and Pharmacodynamic Responses to Oral L-Citrulline in Patients With Sickle Cell Disease

To evaluate PK and PD responses to L-citrulline given orally for four weeks to patients with sickle cell disease who are otherwise healthy.

Phase 1, single center, open label, multiple-dose study consisting of a screening period followed by four weeks of treatment. At least 12 male and female patients, 10 years of age or older, with sickle cell disease but otherwise healthy, will be enrolled in the study.

PK measurements include plasma concentrations of L-citrulline, L-arginine, L-ornithine, and L-proline following the first dose of orally administered L-citrulline and after four weeks of twice daily administration of the drug.

PD measurements include intercellular and vascular adhesion molecules (ICAM, VCAM, and E-selectin), surrogate markers of sickle cell disease activity, and PAT, a measurement of vascular function.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Sickle Cell Disease
Drug: L-citrulline tablets, 1000 mg
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
12
Not Provided
Not Provided

Inclusion Criteria:

  1. Male or female, 10 years of age or older on the day of dosing, and generally healthy as determined by medical history, physical examination, and laboratory test values
  2. Diagnosis of sickle cell anemia (Hb SS)
  3. For female of child-bearing potential, a negative serum pregnancy test and using an adequate method of contraception
  4. Has signed and received a copy of the written informed consent form approved by the investigator’s Institutional Review Board (IRB), understands the purposes and risks of the study and agrees to follow the restrictions and schedule of procedures as defined by this protocol

Exclusion Criteria:

  1. History of sickle-cell–related pain crisis within two weeks of study
  2. Pregnant or breast feeding
  3. Transfusion within last 90 days
  4. Creatinine >1.5 X upper limit of normal
  5. SGPT > 2 X upper limit of normal
  6. History of allergic reaction to arginine or citrulline product
  7. Requires chronic medication other than study drug that cannot be discontinued during the study period
  8. Unable to take or tolerate oral medications
  9. Unreliable venous access
  10. Noncompliant with regular care
  11. Participation in an investigational drug or medical device study within previous 30 days
  12. In the opinion of the investigator is not a good candidate for participation in the study
Both
10 Years and older
No
United States
 
NCT00343954
ANGX-3227-01
Not Provided
Not Provided
Angiogenix
Not Provided
Principal Investigator: Lakshmanam Krishnamurti, MD Children's Hospital of Pittsburgh, Univ. of Pittsburgh Medical Center
Angiogenix
June 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP